IFNA2 and mycosis fungoides: As a proof of concept, four patients with MF were treated with a combination of TTI-621 and pegylated IFN-α2a via an intra-tumoral injection of 10 mg TTI-621 three times per week for two weeks and 90 mcg pegylated IFN-α2a given subcutaneously weekly (Figure 6a).